M05B - Midler med effekt på benstruktur og mineralisering
Sist oppdatert: Sist revidert:
Sist revidert av:Olav Spigset
- Legemiddelkapittelet bygger på informasjon fra Felleskatalogen, Norsk Legemiddelhåndbok og diverse farmakologiske oppslagsverk
- Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SRD. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327: 469. British Medical Journal
- Kamby C, Pedersen L, Kristensen B. Bisfosfonater ved solide maligne sygdomme. Ugeskr Læger 2005; 167: 379-82. PubMed
- Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327: 469-72. British Medical Journal
- Pavlakis N, Stockler M. Bisphosphonates for breast cancer. (Cochrane Review). I: The Cochrane Library, Issue 1, 2002. The Cochrane Library
- Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68. PubMed
- Diel IJ, Solmayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63. New England Journal of Medicine
- Saarto T, Blomqvist C, Virkkunen P et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19: 10-7. PubMed
- Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-24. PubMed
- Løkken P, Skoglund LA, Skjelbred P. Kjeveosteonekrose ved bisfosfonatbehandling. Tidsskr Nor Lægeforen 2007; 127: 1945-7. PubMed
- Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-91. pmid:17663640 PubMed
- Khan AA, Sándor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008; 35: 1391-7. pmid:18528958 PubMed
- Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2013. pmid:23712442 PubMed
- Sharma A, Chatterjee S, Arbab-Zadeh A, et al. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: Evidence from a meta-analysis. Chest 2013; 144: 1311-22. doi:10.1378/chest.13-0675 DOI
- Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 2013; 346: f114. BMJ (DOI)
- Olav Spigset, overlege, professor dr. med., Avdeling for klinisk farmakologi, St. Olavs Hospital